• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2012 年国际膀胱癌咨询委员会-欧洲泌尿外科协会:病理学。

ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology.

机构信息

Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

出版信息

Eur Urol. 2013 Jan;63(1):16-35. doi: 10.1016/j.eururo.2012.09.063. Epub 2012 Oct 5.

DOI:10.1016/j.eururo.2012.09.063
PMID:23083804
Abstract

CONTEXT

To present a summary of the 2nd International Consultation on Bladder Cancer recommendations on the pathology of bladder cancer using an evidence-based strategy.

OBJECTIVE

To standardize descriptions of the diagnosis and reporting of urothelial carcinoma of the bladder and help optimize uniformity between individual pathology practices and institutions.

EVIDENCE ACQUISITION

A detailed Medline analysis was performed for original articles addressing bladder cancer with regard to pathology. Proceedings from the last 5 yr of major conferences were also searched.

EVIDENCE SYNTHESIS

The major findings are presented in an evidence-based fashion. Large retrospective and prospective data were analyzed.

CONCLUSIONS

Providing the best management for patients with bladder neoplasia relies on close cooperation and teamwork among urologists, oncologists, radiologists, and pathologists.

摘要

背景

使用循证策略,呈现第二届膀胱癌国际咨询会议关于膀胱癌病理学建议的总结。

目的

标准化膀胱癌的诊断和报告描述,帮助优化个体病理实践和机构之间的一致性。

证据获取

对涉及膀胱癌病理学的原始文章进行了详细的 Medline 分析。还搜索了过去 5 年主要会议的会议记录。

证据综合

主要发现以循证的方式呈现。对大量回顾性和前瞻性数据进行了分析。

结论

为患有膀胱癌的患者提供最佳治疗取决于泌尿科医生、肿瘤学家、放射科医生和病理学家之间的密切合作和团队协作。

相似文献

1
ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology.2012 年国际膀胱癌咨询委员会-欧洲泌尿外科协会:病理学。
Eur Urol. 2013 Jan;63(1):16-35. doi: 10.1016/j.eururo.2012.09.063. Epub 2012 Oct 5.
2
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers.2012 年国际膀胱癌咨询委员会-欧洲泌尿外科学会:膀胱癌筛查、诊断和分子标志物
Eur Urol. 2013 Jan;63(1):4-15. doi: 10.1016/j.eururo.2012.09.057. Epub 2012 Oct 4.
3
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.2012 年国际膀胱癌咨询委员会-欧洲泌尿外科学会:膀胱非肌肉浸润性尿路上皮癌。
Eur Urol. 2013 Jan;63(1):36-44. doi: 10.1016/j.eururo.2012.08.061. Epub 2012 Sep 5.
4
Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.膀胱尿路上皮癌,脂质细胞变异型:临床病理特征和杂合性缺失分析。
Am J Surg Pathol. 2010 Mar;34(3):371-6. doi: 10.1097/PAS.0b013e3181cd385b.
5
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.2012 年国际膀胱癌咨询委员会-欧洲泌尿外科学会:浸润性膀胱癌的根治性膀胱切除术和膀胱保存治疗。
Eur Urol. 2013 Jan;63(1):45-57. doi: 10.1016/j.eururo.2012.08.009. Epub 2012 Aug 14.
6
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report.
Hum Pathol. 2015 Jul;46(7):1040-4. doi: 10.1016/j.humpath.2015.03.004. Epub 2015 Mar 25.
7
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.2012 年国际膀胱癌咨询委员会-欧洲泌尿外科协会:膀胱癌化疗-新辅助和辅助治疗。
Eur Urol. 2013 Jan;63(1):58-66. doi: 10.1016/j.eururo.2012.08.010. Epub 2012 Aug 14.
8
Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.内皮素轴在非浸润性和表浅性膀胱癌中的表达:与临床病理和分子预后参数的关系。
Eur Urol. 2009 Nov;56(5):837-45. doi: 10.1016/j.eururo.2008.10.003. Epub 2008 Oct 11.
9
Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.关于《内皮素轴在非侵袭性和浅表侵袭性膀胱癌中的表达:与临床病理和分子预后参数的关系》的编辑评论
Eur Urol. 2009 Nov;56(5):846-7. doi: 10.1016/j.eururo.2008.10.005. Epub 2008 Oct 11.
10
Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.关于《内皮素轴在非侵袭性和浅表侵袭性膀胱癌中的表达:与临床病理和分子预后参数的关系》的编辑评论
Eur Urol. 2009 Nov;56(5):845-6. doi: 10.1016/j.eururo.2008.10.004. Epub 2008 Oct 11.

引用本文的文献

1
Curcumin-Dichloroacetate Hybrid Molecule as an Antitumor Oral Drug against Multidrug-Resistant Advanced Bladder Cancers.姜黄素-二氯乙酸酯杂合分子作为一种抗多药耐药晚期膀胱癌的抗肿瘤口服药物
Cancers (Basel). 2024 Sep 8;16(17):3108. doi: 10.3390/cancers16173108.
2
Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis.晚期尿路上皮癌患者的治疗不足:系统文献回顾和荟萃分析。
Future Oncol. 2024;20(16):1123-1137. doi: 10.2217/fon-2023-0298. Epub 2023 Aug 1.
3
The application value of multi-parameter cystoscope in improving the accuracy of preoperative bladder cancer grading.
多参数膀胱镜在提高膀胱癌术前分级准确性方面的应用价值。
BMC Urol. 2022 Jul 18;22(1):111. doi: 10.1186/s12894-022-01054-z.
4
Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients.分析非肌层浸润性膀胱癌高危型非洲裔美国患者的分子亚型。
Urol Oncol. 2022 Sep;40(9):410.e19-410.e27. doi: 10.1016/j.urolonc.2022.04.013. Epub 2022 May 23.
5
Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.膀胱癌样本的处理与报告:病理学家的观点
Front Surg. 2021 Dec 2;8:754741. doi: 10.3389/fsurg.2021.754741. eCollection 2021.
6
The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis.HER2表达在膀胱癌中的临床意义及预后价值:一项荟萃分析和生物信息学分析
Front Oncol. 2021 Sep 1;11:653491. doi: 10.3389/fonc.2021.653491. eCollection 2021.
7
Diffuse Leukoplakia of the Bladder Ostium-Sparing in Patient Treated with Leuprorelin for Breast Cancer.在接受亮丙瑞林治疗乳腺癌的患者中出现的膀胱开口处弥漫性白斑病,未累及开口处
Case Rep Urol. 2021 Jul 27;2021:9970711. doi: 10.1155/2021/9970711. eCollection 2021.
8
Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System.退伍军人事务部医疗体系中,卡介苗治疗高危非肌肉浸润性膀胱癌患者的预估费用和长期结果。
JAMA Netw Open. 2021 Mar 1;4(3):e213800. doi: 10.1001/jamanetworkopen.2021.3800.
9
Recurrence factors in patients with Keratinizing squamous metaplasia of the bladder after surgical management: a single-center retrospective study.膀胱角化性鳞状化生患者手术治疗后的复发因素:一项单中心回顾性研究
Transl Androl Urol. 2021 Feb;10(2):734-740. doi: 10.21037/tau-20-948.
10
Practice change in the management of metastatic urothelial carcinoma after ASCO 2020.2020年美国临床肿瘤学会(ASCO)会议后转移性尿路上皮癌管理方面的实践变革
World J Clin Oncol. 2020 Dec 24;11(12):976-982. doi: 10.5306/wjco.v11.i12.976.